New study reveals promising findings regarding the ability of Medasense’s NOL monitor to reduce postoperative pain.
Previous
Next
Treating Pain is at the Heart of Medicine
Pain is a major clinical, social and economic problem, affecting quality of life for hundreds of millions of people globally and with annual costs exceeding $1T.1,2 Medasense is transforming the way pain is being assessed and treated worldwide.
Through our breakthrough NOL® AI technology and sensor platform, we quantify pain response to optimize care and avoid overmedication. Medasense’s flagship product, PMD-200™, is used in critical care settings, to visualize pain response and personalize treatment. Our pipeline products apply Medasense’s AI capabilities to lead pain prediction, stratification and prevention strategies.
Industry Collaborations and Commercial Partners
Previous
Next
Eliminate guesswork and meet clinical challenges in assessing pain and improving analgesia.
Clinical Evidence
Clinical studies have demonstrated the impact that NOL monitoring has on patient safety,3 outcomes and savings,4 including 33% reduction in reported postoperative pain.5
Medasense Academy
Welcome to our online and customized education and training program for clinicians and commercial partners.
Global Distribution Network
Click on the map to view in full size
Highlights
Medasense - Our Vision: Transforming the way pain is being assessed and treated worldwide
Play Video
Meeting the challenge of intraoperative pain monitoring
Play Video
Leading clinicians on the importance of monitoring the patient’s pain response level
Play Video
Experience NOL monitoring with the NOL Simulation Hub
REFERENCES:
1. Darrell J. Gaskin, Patrick Richard. The Economic Costs of Pain in the United States. The Journal of Pain, 2012; 13 (8): 715 DOI: 10.1016/j.jpain.2012.03.009
2. EuroStat. Eurostat News release. Eurostat. [Online] 3 30, 2017. https://ec.europa.eu/eurostat/documents/2995521/7962764/1-30032017-AP-EN.pdf/. 52/2017.
3. Meijer, F., Martini, C., Broens, S., Boon, M., Niesters, M., Aarts, L., Olofsen, E., van Velzen, M., Dahan, A. (2019). Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology, 130(5), 745-755. doi:10.1097/ALN.0000000000002634
4. Saunders R., Weissbrod R. (2020). Cost benefit of personalizing intraoperative pain management. Presented at ISPOR Virtual Conference, May 2020
5. Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. British Journal of Anaesthesia, 125(6), 1070-1078.